Immune cells from cord blood aim to wipe out hidden colon cancer
NCT ID NCT05040568
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a combination therapy in 15 people with colon cancer who had completed standard treatment but still had tiny amounts of cancer DNA in their blood (called minimal residual disease). The treatment used specially activated immune cells from donated umbilical cord blood, given together with a targeted drug called cetuximab. The goal was to see if this approach could clear the remaining cancer cells and prevent the disease from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?